The Pathology Core (Core B) will support multiple projects within the program by providing human tissues for esearch. The director of the Pathology Core, Dr. Andrea Richardson, is a board certified pathologist with a specialty in breast pathology. She is director of the breast tissue bank at Brigham and Women's Hospital and oversees the collection, storage, processing and analysis of breast tissues. The breast tissue repository at BWH holds over 1500 breast tumor specimens with full pathology annotation. Many of these specimens have undergone extensive molecular analysts including gene expression array profiling, SNP array genotyping, and are also represented in paraffin-embedded tissue microarrays. In addition to tumor tissues, he BWH repository also collects normal breast tissue specimens from breast reduction surgeries. These normal tissues are stored as frozen samples or can be provided as fresh samples for isolation of normal organoids or breast stem cells. The pathology core will provide normal breast tissue for stem cell studies (Polyak) and for 3-D organoid cultures (Brugge). Fresh tumor samples will be provided to establish primary tumor xenografts in mice Weinberg). In addition, Dr. Richardson will participate in the pathologic comparisons, both molecular and histology, between the parent human tumors and the resultant xenografts. Gene expression array data obtained from human tumors will be used in system interaction analyses of BRCA1 related pathways (Livingston). Dr. Richardson will provide both tissue and scientific expertise to analyze frozen tumor specimens and paraffin tissue microarrays for the expression of BRCA1 gene products, including IRIS (Livingston).

Public Health Relevance

Research using actual human breast tissue and breast tumor material will hopefully provide the most relevant answers to pathogenesis and tumor behavior of breast cancer in women. PROJECT/

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA080111-15
Application #
8449511
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$12,921
Indirect Cost
$1,744
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Zhang, Jinfang; Xu, Kai; Liu, Pengda et al. (2016) Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol Cell 62:929-42
Spiegel, Asaf; Brooks, Mary W; Houshyar, Samin et al. (2016) Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discov 6:630-49
Shu, Shaokun; Lin, Charles Y; He, Housheng Hansen et al. (2016) Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529:413-7
Hydbring, Per; Malumbres, Marcos; Sicinski, Piotr (2016) Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol 17:280-92
De Cock, Jasmine M; Shibue, Tsukasa; Dongre, Anushka et al. (2016) Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. Cancer Res 76:6778-6784
Malorni, Luca; Giuliano, Mario; Migliaccio, Ilenia et al. (2016) Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res 14:470-81
Fu, Xiaoyong; Jeselsohn, Rinath; Pereira, Resel et al. (2016) FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A 113:E6600-E6609
Huh, Sung Jin; Oh, Hannah; Peterson, Michael A et al. (2016) The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. Cancer Res 76:1926-34
Wang, Hua; Bierie, Brian; Li, Andrew G et al. (2016) BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. Mol Cell 63:277-92
Goel, Shom; Wang, Qi; Watt, April C et al. (2016) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell 29:255-69

Showing the most recent 10 out of 114 publications